The tumour response of postmenopausal hormone receptor-positive breast cancers undergoing different types of neoadjuvant therapy: a meta-analysis

Table 2 The treatment regimen of neoadjuvant therapy

Study	Year	NET	NCT	NCET
Chae [24]	2016	Letrozole qd	FEC, a switch to docetaxel if PD or SD
Wright [25]	2015	AIs or tamoxifen qd	PAT or AT
Palmieri [26]	2014	Letrozole qd	FE100C or FE75C, a switch to docetaxel if PD or SD
Semiglazov [27]	2007	Exemestane or anastrozole qd	Doxorubicin + paclitaxel
Marcus [28]	2013	AIs or tamoxifen qd	Anthracycline-based or non-anthracycline-based
Ellis [29]	2017	AIs qd^a	Anthracycline-based or non-anthracycline-based
Nakayama [30]	2018	Anastrozole qd		Anastrozole qd + UFT
Sato [31]	2018	Exemestane qd		Exemestane qd + cyclophosphamide
Sugiu [32]	2015		FEC-T	Exemestane qd + EFC-T
Mohammad [33]	2012		FAC	Letrozole qd + FAC

Explanation of regimen: FEC, 5-fluorouracil, epirubicin, and cyclophosphamide; FE100C, 5-fluorouracil 500 mg/m², cyclophosphamide 500 mg/m², epirubicin 100 mg/m²; FE75C, 5-fluorouracil 600 mg/m², cyclophosphamide 600 mg/m², epirubicin 75 mg/m²; UFT, tegafur/uracil combination in 1:4 M ratio; 270 mg/m²/day in two divided doses; FEC-T, 80 mg/m² of paclitaxel followed by a combination of fluorouracil 500 mg/m², epirubicin 100 mg/m² and cyclophosphamide 500 mg/m²; FAC, 5-Fluorouracil 600 mg/m², doxorubicin 60 mg/m² and cyclophosphamide 600 mg/m²
Abbreviations: NET Neoadjuvant endocrine therapy, NCT Neoadjuvant chemotherapy, NCET Neoadjuvant chemoendocrine therapy, AIs Aromatase inhibitors, PD Progressive disease, SD Stable disease
^aThese aromatase inhibitors include letrozole, anastrozole and exemestane

ISSN: 1472-6874